Clinical trial NCT01484067: Study of a Cold Sore Patch for the Treatment of Herpes Labialis
Official title: A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of Compeed© Total Care™ Cold Sore Patch With Zinc Sulfate for the Treatment of Herpes Labialis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Herpes Labialis
Keywords: Herpes Simplex Virus
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide
Sponsor class: INDUSTRY
First posted: 2011-12-02
Enrollment: 472
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: If a person qualifies to participate in this study, they will have an equal chance of being assigned to either of two groups. One group will receive a patch that they will need to carry with them, because as soon as a cold sore starts (within 1 hour) they will need to put the patch over the sore. The other group will not get a patch, but will need to follow the other instructions anyway.

When a subject's outbreak begins, they will need to return to the study center within 24 hours. Then they will return according to the appointments given within 10 days. If the study staff sees that their sore has healed enough before 10 days, subjects will be told that they don't need to return again.

As long as subjects are in the study, they will need to answer a few simple questions every day on a card or booklet called a diary, starting the first day of their outbreak. If a subject is assigned to the patch group, they must wear the patch all the time, taking it off only to replace it (if it gets loose, dirty, or unsightly) and at the study center, when they are asked to remove the patch so the sore can be checked.

During the study subjects will be allowed to use paracetamol for pain, but no other treatments or medicine. If they use paracetamol, subjects must record it in their diary. The study will be stopped, and there will be no subject visits or treatments during the end of year holiday break. If a subject experiences an outbreak during the holiday, they may follow their usual treatment routine.

Detailed description: This is a two-arm, randomized, clinician-blind study. No severe adverse effects are expected to be experienced in the control group. All subjects are allowed to treat cold sore related pain with an oral analgesic - paracetamol (APAP). The use of APAP for pain will be recorded as a concomitant medication. However, subjects will be required to refrain from using any additional treatment (topical or systemic) during study participation.

Subjects randomized to treatment will be instructed to initiate the therapy within 1 hour onset of their first sign or symptom and record their assessment in the diary card (for no treatment subjects, they will only record assessments upon onset of first sign or symptom). All subjects will return to the study center for clinical assessments within 24 hours and 48 hours after onset of first sign or symptom/initiation of treatment and every other day thereafter, with a final visit at Day 10 or at the time of completion/discontinuation if before Day 10. Diaries will be completed each day, beginning upon initiation of therapy (Day 0) and continuing until study completion/discontinuation, and will include information on study product applications.

Subjects assigned to a patch treatment will wear a patch continuously on their lesion and will apply a new patch on occasions where the patch becomes loose, falls off or becomes unsightly, including at study visits to the facility where subjects will be asked to remove their patch for clinical assessments. Treatment will continue until the lesion is healed, for a maximum of 10 days. As the test period will possibly extend through the end of year holiday break, subject visits and treatments will be halted during this break. All subjects who have not initiated therapy including subjects assigned no treatment group, will be allowed to use their regular therapy for a cold sore outbreak during the holiday break.

Eligibility criteria: Inclusion Criteria:

* Female or male 18-70 years old in good general health
* Has a history of Herpes Labialis in the areas and with the frequency defined in the protocol.
* Based on history, likely to experience a cold sore outbreak within next 2 to 3 months
* Willing to provide informed consent
* Willing to stop all other treatment of this condition and any topical products (lip balm, cosmetics, sunscreen) during test period
* Women of child bearing potential must agree to use an adequate method of birth control (systemic birth control/intrauterine device)

Exclusion Criteria:

* Self-reported to be pregnant, planning to become pregnant or nursing
* Has any medical history or condition that might, per protocol or in the opinion of the investigator, compromise the subject's safety or the analysis of results.
* Is taking or has taken within the 28 days before commencing treatment, protocol-specified medications or herbal supplements.

Primary outcomes:
measure: Overall Condition of Cold Sore
timeFrame: Within 10 Days
measure: Erythema
timeFrame: Within 10 Days
measure: Edema
timeFrame: Within 10 Days
measure: Vesicles
timeFrame: Within 10 Days
measure: Scab/Crust
timeFrame: Within 10 Days
Secondary outcomes:
measure: Lesion Size
timeFrame: Within 10 Days
measure: Lesion Stage
timeFrame: Within 10 Days
measure: Pain
timeFrame: Within 10 Days
measure: Discomfort
timeFrame: Within 10 Days
measure: Itching
timeFrame: Within 10 days
measure: Burning
timeFrame: Within 10 Days
measure: Tingling
timeFrame: Within 10 Days
measure: Swelling
timeFrame: Within 10 Days
measure: Soreness/Tenderness
timeFrame: Within 10 Days
measure: Redness
timeFrame: Within 10 Days
measure: Blisters
timeFrame: Within 10 Days
measure: Scab or Crust
timeFrame: Within 10 Days
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Intertek CRS
Study officials:
affiliation: Johnson & Johsnon Consumer and Personal Products Worldwide
name: Clare Kendall
role: STUDY_DIRECTOR
References: